UK markets closed

Medigene AG (0QGJ.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
1.1750-0.0050 (-0.42%)
At close: 02:19PM BST

Medigene AG

Lochhamer Strasse 11
Planegg/Martinsried
Munich 82152
Germany
49 89 2000 330
https://www.medigene.com

Sector(s)
Industry
Full-time employees76

Key executives

NameTitlePayExercisedYear born
Dr. Selwyn Ho MB BS, MBBSCEO & Chairman of Executive Management Board384.47kN/A1971
Dr. Dolores J. SchendelChief Scientific Officer, Member of Executive Management Board and Head of Research & Development600kN/AN/A
Dr. Ernst-Ludwig WinnackerCo-Founder & Chairman Scientific Advisory Board20kN/A1941
Dr. Birger KohlertChief Financial OfficerN/AN/AN/A
Pamela KeckVice President of Investor Relations & Corporate CommunicationsN/AN/AN/A
Dr. Kirsty Crame M.D.VP and Head of Clinical Research & DevelopmentN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer. It also focuses on dendritic cell vaccines. Medigene AG has a strategic partnership with BioNTech to develop TCRbased immunotherapies against cancer; and 2seventy bio, Inc. for the development of TCR immunotherapies, as well as a collaboration agreement with National Cancer Institute to evaluate the potential of T cell receptors to be used in new cell constructs for the treatment of solid tumors. It has operations in Germany, the United States, and Asia. The company was founded in 1994 and is headquartered in Munich, Germany.

Corporate governance

Medigene AG’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.